...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of cutaneous medicine and surgery >Combination oral prednisone and intravenous immunoglobulin in the treatment of scleromyxedema.
【24h】

Combination oral prednisone and intravenous immunoglobulin in the treatment of scleromyxedema.

机译：口服泼尼松和静脉注射免疫球蛋白联合治疗巩膜水肿。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Scleromyxedema is a clinical variant of the rare disease papular mucinosis that has both cutaneous and systemic manifestations. Treatment options are numerous and tend to be associated with serious potential side effects and frequent relapse. OBJECTIVE: We report a case of scleromyxedema treated with low-dose oral prednisone and intravenous immunoglobulin (IVIg). This is followed by a review of the literature. CONCLUSION: IVIg is being used for a growing number of inflammatory and immune disorders. It is being increasingly reported as a successful treatment for scleromyxedema. Although our patient succumbed to the disease, combination therapy with prednisone and IVIg provided temporary symptomatic, laboratory, and clinical improvement of the condition. Optimization of this therapeutic strategy is thus indicated for the management of scleromyxedema.
机译：背景：巩膜水肿是罕见的丘疹性粘液病的临床变种，具有皮肤和全身表现。治疗选择很多，并且往往与严重的潜在副作用和频繁复发有关。目的：我们报道一例小剂量口服泼尼松和静脉注射免疫球蛋白（IVIg）治疗的巩膜水肿。接下来是文献综述。结论：IVIg被用于越来越多的炎症和免疫疾病。越来越多的报道将其作为硬化性水肿的成功治疗方法。尽管我们的患者死于这种疾病，但泼尼松和IVIg的联合治疗可暂时改善症状，实验室和临床症状。因此表明该治疗策略的优化用于硬化性水肿的管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号